MHRA trailing stem cell robot that could transform the availability of cell therapies

MHRA trailing stem cell robot that could transform the availability of cell therapies

An innovative new robot that grows stem cells – the CellQualiaIntelligent Cell Processing System – is being trialled by the Medicines and Healthcare products Regulatory Agency (MHRA). This robotic system has the potential to bring safer and more cost-effective treatments to people with a wide range of diseases. It is currently the only one in the world outside of Japan, where it was developed.

Stem cells have a unique ability to turn into different types of cells with specialised functions. This makes them particularly useful in medicine because they can replace cells that have been damaged or lost from disease – for example restoring eyesight after corneal disease.

“At the MHRA, we’re committed to being at the forefront of the latest scientific developments so that we can help bring safe and effective treatments to the people who need them most,” said Marc Bailey, Chief Scientific Officer, MHRA. “Cell-based therapeutics have the potential to treat, and even cure, a vast number of diseases but their availability has been limited because they are often very difficult to manufacture.”

Because stem cell-based therapeutics are difficult to manufacture, their current availability is limited. This means that most treatments for degenerative diseases are focused on limiting the extent of damage rather than fixing the damage that has already occurred. The system being tested at the MHRA has the potential to change this, offering new hope to patients with serious diseases such as Parkinson’s.

This trial is part of a UK-based international research programme, launched in 2021, and a partnership between the MHRA, SAKARTA (a Scottish Regenerative Medicine start-up) and Sinfonia Technology Co. Ltd (a Tokyo-based electrical equipment manufacturer), supported by Foundation for Biomedical Research and Innovation at Kobe (FBRI). The UK Stem Cell Bank is testing the robot over a 12-month period to see whether the cells produced by the fully automated Intelligent Cell Processing System meet the standards needed for them to be used in the manufacture of potentially life-saving treatments.

“The new Intelligent Cell Processing System being tested at the MHRA – which there are only two machines in use in the world – could make this manufacturing process much easier and therefore transform the availability of these treatments,” added Bailey. “It also has the potential to reduce human error in this process and produce a more consistent final product which will result in safer and more effective treatments. We look forward to communicating the results of our testing.”

Click below to share this article